Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Regen BioPharma (RGBP) over the last 13 years, with Q2 2025 value amounting to -$0.01.

  • Regen BioPharma's EPS (Basic) rose 6666.67% to -$0.01 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.2, marking a year-over-year change of 0.0%. This contributed to the annual value of -$0.16 for FY2024, which is 15618.39% down from last year.
  • According to the latest figures from Q2 2025, Regen BioPharma's EPS (Basic) is -$0.01, which was up 6666.67% from -$0.0 recorded in Q1 2025.
  • Regen BioPharma's EPS (Basic)'s 5-year high stood at $19.06 during Q2 2022, with a 5-year trough of -$22.04 in Q1 2022.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.02 (2023), whereas its average is -$0.16.
  • The largest annual percentage gain for Regen BioPharma's EPS (Basic) in the last 5 years was 90974165.33% (2022), contrasted with its biggest fall of 1418088484.19% (2022).
  • Over the past 5 years, Regen BioPharma's EPS (Basic) (Quarter) stood at $0.0 in 2021, then surged by 81142.53% to $0.43 in 2022, then tumbled by 109.28% to -$0.04 in 2023, then crashed by 213.47% to -$0.13 in 2024, then skyrocketed by 92.02% to -$0.01 in 2025.
  • Its EPS (Basic) was -$0.01 in Q2 2025, compared to -$0.0 in Q1 2025 and -$0.13 in Q4 2024.